240 related articles for article (PubMed ID: 10903745)
1. Identification of class II transcriptional activator-induced genes by representational difference analysis: discoordinate regulation of the DN alpha/DO beta heterodimer.
Taxman DJ; Cressman DE; Ting JP
J Immunol; 2000 Aug; 165(3):1410-6. PubMed ID: 10903745
[TBL] [Abstract][Full Text] [Related]
2. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.
Lu HT; Riley JL; Babcock GT; Huston M; Stark GR; Boss JM; Ransohoff RM
J Exp Med; 1995 Nov; 182(5):1517-25. PubMed ID: 7595221
[TBL] [Abstract][Full Text] [Related]
3. X box-like sequences in the MHC class II region maintain regulatory function.
Gomez JA; Majumder P; Nagarajan UM; Boss JM
J Immunol; 2005 Jul; 175(2):1030-40. PubMed ID: 16002703
[TBL] [Abstract][Full Text] [Related]
4. Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation.
Masternak K; Reith W
EMBO J; 2002 Mar; 21(6):1379-88. PubMed ID: 11889043
[TBL] [Abstract][Full Text] [Related]
5. The transcription factor RFX protects MHC class II genes against epigenetic silencing by DNA methylation.
Seguín-Estévez Q; De Palma R; Krawczyk M; Leimgruber E; Villard J; Picard C; Tagliamacco A; Abbate G; Gorski J; Nocera A; Reith W
J Immunol; 2009 Aug; 183(4):2545-53. PubMed ID: 19620312
[TBL] [Abstract][Full Text] [Related]
6. Discoordinate surface expression of IFN-gamma-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization.
Muczynski KA; Anderson SK; Pious D
J Immunol; 1998 Apr; 160(7):3207-16. PubMed ID: 9531276
[TBL] [Abstract][Full Text] [Related]
7. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter.
Deffrennes V; Vedrenne J; Stolzenberg MC; Piskurich J; Barbieri G; Ting JP; Charron D; Alcaïde-Loridan C
J Immunol; 2001 Jul; 167(1):98-106. PubMed ID: 11418637
[TBL] [Abstract][Full Text] [Related]
8. CIITA-induced occupation of MHC class II promoters is independent of the cooperative stabilization of the promoter-bound multi-protein complexes.
Villard J; Muhlethaler-Mottet A; Bontron S; Mach B; Reith W
Int Immunol; 1999 Mar; 11(3):461-9. PubMed ID: 10221658
[TBL] [Abstract][Full Text] [Related]
9. Long distance control of MHC class II expression by multiple distal enhancers regulated by regulatory factor X complex and CIITA.
Krawczyk M; Peyraud N; Rybtsova N; Masternak K; Bucher P; Barras E; Reith W
J Immunol; 2004 Nov; 173(10):6200-10. PubMed ID: 15528357
[TBL] [Abstract][Full Text] [Related]
10. Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.
Sartoris S; Tosi G; De Lerma Barbaro A; Cestari T; Accolla RS
Eur J Immunol; 1996 Oct; 26(10):2456-60. PubMed ID: 8898960
[TBL] [Abstract][Full Text] [Related]
11. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex.
Masternak K; Muhlethaler-Mottet A; Villard J; Zufferey M; Steimle V; Reith W
Genes Dev; 2000 May; 14(9):1156-66. PubMed ID: 10809673
[TBL] [Abstract][Full Text] [Related]
12. Class II transactivator is required for maximal expression of HLA-DOB in B cells.
Nagarajan UM; Lochamy J; Chen X; Beresford GW; Nilsen R; Jensen PE; Boss JM
J Immunol; 2002 Feb; 168(4):1780-6. PubMed ID: 11823510
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells.
Liu A; Takahashi M; Toba K; Zheng Z; Hashimoto S; Nikkuni K; Furukawa T; Koike T; Aizawa Y
Hematol Oncol; 1999 Dec; 17(4):149-60. PubMed ID: 10725870
[TBL] [Abstract][Full Text] [Related]
14. The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes.
Kern I; Steimle V; Siegrist CA; Mach B
Int Immunol; 1995 Aug; 7(8):1295-9. PubMed ID: 7495736
[TBL] [Abstract][Full Text] [Related]
15. Novel mutations within the RFX-B gene and partial rescue of MHC and related genes through exogenous class II transactivator in RFX-B-deficient cells.
Nagarajan UM; Peijnenburg A; Gobin SJ; Boss JM; van den elsen PJ
J Immunol; 2000 Apr; 164(7):3666-74. PubMed ID: 10725724
[TBL] [Abstract][Full Text] [Related]
16. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity.
Sartoris S; Valle MT; Barbaro AL; Tosi G; Cestari T; D'Agostino A; Megiovanni AM; Manca F; Accolla RS
J Immunol; 1998 Jul; 161(2):814-20. PubMed ID: 9670958
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction.
Chin KC; Mao C; Skinner C; Riley JL; Wright KL; Moreno CS; Stark GR; Boss JM; Ting JP
Immunity; 1994 Nov; 1(8):687-97. PubMed ID: 7600294
[TBL] [Abstract][Full Text] [Related]
18. Increased binding of IFN regulating factor 1 mediates the synergistic induction of CIITA by IFN-gamma and tumor necrosis factor-alpha in human thyroid carcinoma cells.
Rahat MA; Chernichovski I; Lahat N
Int Immunol; 2001 Nov; 13(11):1423-32. PubMed ID: 11675374
[TBL] [Abstract][Full Text] [Related]
19. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
[TBL] [Abstract][Full Text] [Related]
20. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
